Cidara Therapeutics Inc (CDTX) - News Archive

Cidara Therapeutics Set to Showcase Promising Data for CD388 at ID Week 2025 amid Challenging Financial Landscape Cidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology company known for its innovative Clo...

In a significant development within the realm of infectious disease management, Cidara Therapeutics has announced the commencement of its Phase 3 ANCHOR trial, which aims to evaluate the efficacy of CD388 in preventing...

In recent news, Cidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology firm renowned for its innovative Cloudbreak platform, announced the allocation of stock options and restricted stock units (RSUs) to D...

Cidara Therapeutics, Inc. has recently announced pivotal steps in its strategic focus on the development of CD388, an innovative drug-Fc conjugate (DFC) candidate aimed at combating influenza A and B. This comprehensive...

Cidara Therapeutics Advances with NAVIGATE Trial and Strategic Divestiture DecisionCidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology company, has recently set significant milestones in its strategic t...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a leading biotechnology company based in San Diego, has recently announced a notable expansion of its Scientific Advisory Board (SAB) by appointing four distinguished experts in...

Cidara Therapeutics Restructures Workforce to Prioritize Clinical Development of CD388Cidara Therapeutics, Inc. (Nasdaq: CDTX), headquartered in San Diego, is a biotechnology company that has been gaining attention in t...

Cidara Therapeutics Grants New Employee Stock Options and RSUs under Nasdaq RuleThe biotechnology company, Cidara Therapeutics, Inc., known for its innovative Cloudbreak platform aimed at developing drug-Fc conjugate (D...

SAN DIEGO, May 30, 2024Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company leveraging its proprietary Cloudbreak® platform to develop innovative drug-Fc conjugate (DFC) immunotherapies, is poised to make a...

The Ivy Coast of Wall Street: Cidara Therapeutics Legal Quagmire UnveiledCidara Therapeutics Inc. (NASDAQ: CDTX), a leading bio-pharmaceutical company, finds itself in the middle of a mounting legal storm, as Rosen Law...

In a recent development, Cidara Therapeutics, a biotechnology company specializing in drug-Fc conjugate (DFC) immunotherapies, has announced the divestiture of rezafungin to Mundipharman. This strategic move allows Cida...

A Milestone Achievement: Cidara Therapeutics Receives $11.14 Million Payment and Improves Leverage RatioSan Diego-based biotechnology company, Cidara Therapeutics, Inc., announced the receipt of an $11.14 million milest...

The health and wellness sector announces a breakthrough as the European Union (EU) gives the green light for REZZAYO (rezafungin acetate), a proactive solution in the fight against invasive candidiasis in adults. The ap...

Cidara Therapeutics, a renowned biotechnology company, recently unveiled groundbreaking preclinical data on two of its novel drug candidates at the ESMO Immuno-Oncology Annual Congress. The presentations centered around...

In an exciting development for the medical community, Melinta Therapeutics and Cidara Therapeutics have proudly announced the publication of landmark research assessing the efficacy and safety of their innovative drug,...

Cidara Therapeutics, a biotechnology company specializing in the development of innovative therapies for cancer treatment, is set to unveil groundbreaking preclinical data on their novel dual-acting drug-Fc conjugates a...

SAN DIEGO and CAMBRIDGE, England – Cidara Therapeutics, a leading biotechnology company, and Mundipharma, a pharmaceutical powerhouse, have announced a major breakthrough in the treatment of invasive candidiasis in adul...

Cidara Therapeutics Grants New Employee, Dr. Nicole Davarpanah, Stock Options and Restricted Stock UnitsSan Diego-based biotechnology company, Cidara Therapeutics, Inc. (Nasdaq:CDTX), has granted Dr. Nicole Davarpanah,...